[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@keisan_15 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::894947082196353024.png) @keisan_15 Kさん

Kさん posts on X about $tngx, $rvmd, $psnl, cash flow the most. They currently have XX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::894947082196353024/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::894947082196353024/c:line/m:interactions.svg)

- X Week XXX +189%
- X Month XXXXX -XX%
- X Months XXXXXX +8,195%
- X Year XXXXXX +3,980%

### Mentions: X [#](/creator/twitter::894947082196353024/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::894947082196353024/c:line/m:posts_active.svg)


### Followers: XX [#](/creator/twitter::894947082196353024/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::894947082196353024/c:line/m:followers.svg)

- X Week XX +1.20%
- X Month XX +6.40%
- X Months XX +152%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::894947082196353024/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::894947082196353024/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance) 

**Social topic influence**
[$tngx](/topic/$tngx) #6, [$rvmd](/topic/$rvmd) #19, [$psnl](/topic/$psnl), [cash flow](/topic/cash-flow), [flow](/topic/flow), [$gral](/topic/$gral), [to the](/topic/to-the), [$fro](/topic/$fro), [guess](/topic/guess), [looking for](/topic/looking-for)

**Top accounts mentioned or mentioned by**
[@earlyvotedata](/creator/undefined) [@honestpollster](/creator/undefined) [@peoplespundit](/creator/undefined) [@christianheiens](/creator/undefined) [@geigercapital](/creator/undefined) [@zerohedge](/creator/undefined) [@inezfeltscher](/creator/undefined) [@datarepublican](/creator/undefined) [@rasmussenpoll](/creator/undefined) [@osint613](/creator/undefined) [@admcrlsn](/creator/undefined) [@bananaoncology](/creator/undefined) [@douthatnyt](/creator/undefined) [@realdonaldtrump](/creator/undefined) [@danpfeiffer](/creator/undefined) [@grok](/creator/undefined) [@usdpcolby](/creator/undefined) [@iapolls2022](/creator/undefined) [@avidresearch](/creator/undefined) [@thedatagooroo](/creator/undefined)

**Top assets mentioned**
[Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) [GRAIL, Inc. Common Stock (GRAL)](/topic/$gral) [Frontline Ltd. (FRO)](/topic/$fro)
### Top Social Posts
Top posts by engagements in the last XX hours

"Basically if $PSNL ever dipped below $7-9 (depending on your conviction) I'd buy buy buy today. Price point goes higher as you get more confirmation of the volume and cash flow story through '26/'27"  
[X Link](https://x.com/keisan_15/status/1996243080219951272)  2025-12-03T15:40Z XX followers, XXX engagements


"But how does $GRAL change the story and competitive space if it gets into MRD Should we be worried"  
[X Link](https://x.com/keisan_15/status/1996243362555281472)  2025-12-03T15:41Z XX followers, XXX engagements


"Better Sensitivity table. Forgot to change some numbers. Think of the left $1150 column representing a baseline where reimbursement is medicare only. Right gets to a more normal commercial reimbursement mix (1.4x premium multiplier). Again DCF so a conservative valuation"  
[X Link](https://x.com/keisan_15/status/1995687728181399610)  2025-12-02T02:53Z XX followers, XXX engagements


"In other news $TNGX fireside chat today at Piper HC conferece 1:30 et"  
[X Link](https://x.com/keisan_15/status/1996247766025072805)  2025-12-03T15:58Z XX followers, XXX engagements


"Initial takeaway from the $TNGX chat: they love $RVMD"  
[X Link](https://x.com/keisan_15/status/1996292748723298595)  2025-12-03T18:57Z XX followers, XXX engagements


"$TNGX Research Director Adam Crystal today: "Pancreatic cancer is fortunately changing very quickly for patientsKRAS inhibitors will likely be approved next year Daraxonrasib specifically in the second line. And we believe that it will quickly advance to the front-line"  
[X Link](https://x.com/keisan_15/status/1996357608731762953)  2025-12-03T23:15Z XX followers, XXX engagements


"$RVMD $TNGX TNG462/RMC-6236 Combo PDAC Trial PoS: ORR XX% - 30-40% PoS ORR XX% - XX% PoS mPFS 10mo - XX% PoS Agree Disagree Way too optimistic"  
[X Link](https://x.com/keisan_15/status/1996701716230590922)  2025-12-04T22:02Z XX followers, XXX engagements


"@midwit_capital @houndcl Yeah I guess I'm just looking for input from @Banana_Oncology (and others) on the acquisition in terms of Signatera vs NeXT. Again with the overall TAM and esp with Tempus' existing base lots of runway still for PSNL. And the royalty is nice"  
[X Link](https://x.com/keisan_15/status/1996991935467172350)  2025-12-05T17:15Z XX followers, XXX engagements